- Home
- MTLS vs ATAI Comparison
MTLS vs ATAI Comparison
Compare MTLS & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- ATAI
- Stock Information
- Founded
- MTLS 1990
- ATAI 2018
- Country
- MTLS Belgium
- ATAI Germany
- Employees
- MTLS N/A
- ATAI N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- MTLS Technology
- ATAI Health Care
- Exchange
- MTLS Nasdaq
- ATAI Nasdaq
- Market Cap
- MTLS 297.1M
- ATAI 271.6M
- IPO Year
- MTLS 2014
- ATAI 2021
- Fundamental
- Price
- MTLS $5.21
- ATAI $1.52
- Analyst Decision
- MTLS Buy
- ATAI Strong Buy
- Analyst Count
- MTLS 1
- ATAI 4
- Target Price
- MTLS $9.50
- ATAI $9.00
- AVG Volume (30 Days)
- MTLS 292.3K
- ATAI 1.8M
- Earning Date
- MTLS 04-24-2025
- ATAI 03-17-2025
- Dividend Yield
- MTLS N/A
- ATAI N/A
- EPS Growth
- MTLS 106.79
- ATAI N/A
- EPS
- MTLS 0.24
- ATAI N/A
- Revenue
- MTLS $276,182,835.00
- ATAI $308,000.00
- Revenue This Year
- MTLS $6.55
- ATAI N/A
- Revenue Next Year
- MTLS $9.21
- ATAI $20.00
- P/E Ratio
- MTLS $21.61
- ATAI N/A
- Revenue Growth
- MTLS 4.15
- ATAI N/A
- 52 Week Low
- MTLS $4.70
- ATAI $0.78
- 52 Week High
- MTLS $9.69
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- MTLS 37.42
- ATAI 50.35
- Support Level
- MTLS $5.01
- ATAI $1.37
- Resistance Level
- MTLS $5.46
- ATAI $1.48
- Average True Range (ATR)
- MTLS 0.18
- ATAI 0.10
- MACD
- MTLS 0.12
- ATAI 0.02
- Stochastic Oscillator
- MTLS 59.32
- ATAI 79.71
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, Poland, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.